Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Hepatocyte Transplantation in Liver Cirrhosis
NCT04806581Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic hepatocyte in Liver cirrhosis (LC) (3 arms), sponsored by Renji Hospital. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicities at 28 days. Status: unknown.
02
Drugs
allogeneic hepatocyte
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04806581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806581.